The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2696-2703

  Gantt, Soren ^a,c   Carlsson, Jacquelyn ^c   Ikoma, Minako ^b   Gachelet, Eliora ^b   Gray, Matthew ^b   Geballe, Adam P ^b,d   Corey, Lawrence ^b,d   Casper, Corey ^b,d   Lagunoff, Michael ^b   Vieira, Jeffrey ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; ALKALINE PHOSPHATASE; AMPRENAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; KAPOSI SARCOMA; LYMPHOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS REPLICATION;

ADENOVIRIDAE; ALKALINE PHOSPHATASE; ANIMALS; CERCOPITHECUS AETHIOPS; CYTOMEGALOVIRUS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 8, HUMAN; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; VACCINIA VIRUS; VERO CELLS; VIRUS REPLICATION;

EID: 79956301430     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01295-10     Document Type: Article

References (58)

1. Antman, K., and Y. Chang. 2000. Kaposi's sarcoma. N. Engl. J. Med. 342:1027-1038.
2. Bani-Sadr, F., S. Fournier, and J. M. Molina. 2003. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS 17:1580-1581.
3. Bardsley-Elliot, A., and G. L. Plosker. 2000. Nelfinavir: an update on its use in HIV infection. Drugs 59:581-620.
4. Berger, J., J. Hauber, R. Hauber, R. Geiger, and B. R. Cullen. 1988. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 66:1-10.
5. Bilello, J. P., J. S. Morgan, B. Damania, S. M. Lang, and R. C. Desrosiers. 2006. A genetic system for rhesus monkey rhadinovirus: use of recombinant virus to quantitate antibody-mediated neutralization. J. Virol. 80:1549-1562.
6. Boeckh, M., and P. Ljungman. 2009. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711-5719.
7. Carroll, P. A., E. Brazeau, and M. Lagunoff. 2004. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 328:7-18. (Pubitemid 39221907)
8. Casper, C., et al. 2008. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J. Infect. Dis. 198:23-30.
9. Casper, C., W. G. Nichols, M. L. Huang, L. Corey, and A. Wald. 2004. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:1632-1634. (Pubitemid 38268952)
10. Casper, C., et al. 2004. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J. Acquir. Immune Defic. Syndr. 35:233-238.
11. Cattelan, A. M., et al. 2001. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J. Natl. Cancer Inst. Monogr. 28:44-49.
12. Chakrabarti, S., K. Brechling, and B. Moss. 1985. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403-3409.
13. Chandler, B., et al. 2003. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defic. Syndr. 33:551-556.
14. Child, S. J., M. Hakki, K. L. De Niro, and A. P. Geballe. 2004. Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J. Virol. 78:197-205.
15. Child, S. J., L. K. Hanson, C. E. Brown, D. M. Janzen, and A. P. Geballe. 2006. Double-stranded RNA binding by a heterodimeric complex of murine cytomegalovirus m142 and m143 proteins. J. Virol. 80:10173-10180.
16. Chow, W. A., S. Guo, and F. Valdes-Albini. 2006. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. Anticancer Drugs 17:891-903. (Pubitemid 44350608)
17. Chow, W. A., C. Jiang, and M. Guan. 2009. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 10:61-71.
18. Corey, L., A. Wald, C. L. Celum, and T. C. Quinn. 2004. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35:435-445.
19. Cullen, B. R. 2000. Utility of the secreted placental alkaline phosphatase reporter enzyme. Methods Enzymol. 326:159-164.
20. Engels, E. A., et al. 2003. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 17:1847-1851. (Pubitemid 37000104)
21. Gill, J., et al. 2002. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 31:384-390.
22. Gills, J. J., et al. 2007. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13:5183-5194.
23. Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 89:5547-5551.
24. Grundhoff, A., and D. Ganem. 2004. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Invest. 113:124-136.
25. Gupta, A. K., G. J. Cerniglia, R. Mick, W. G. McKenna, and R. J. Muschel. 2005. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. 65:8256-8265.
26. Jenwitheesuk, E., and R. Samudrala. 2005. Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics. AIDS 19:529-531. (Pubitemid 40515858)
27. Joffe, M. M., et al. 1997. Effect of treatment with zidovudine on subsequent incidence of Kaposi's sarcoma. Clin. Infect. Dis. 25:1125-1133.
28. Kedes, D. H., and D. Ganem. 1997. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J. Clin. Invest. 99:2082-2086.
29. Lagunoff, M., et al. 2002. De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J. Virol. 76:2440-2448. (Pubitemid 34150712)
30. Leitch, H., M. Trudeau, and J. P. Routy. 2003. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin. Trials 4:107-114.
31. Limaye, A. P. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35:866-872.
32. Lock, M. J., N. Thorley, J. Teo, and V. C. Emery. 2002. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J. Antimicrob. Chemother. 49:359-366.
33. Markowitz, M., et al. 1998. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177:1533-1540.
34. Martin, D. F., et al. 1999. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 340:1063-1070.
35. Medveczky, M. M., E. Horvath, T. Lund, and P. G. Medveczky. 1997. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 11:1327-1332.
36. Mocroft, A., et al. 1996. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 10:1101-1105. (Pubitemid 26283347)
37. Morris, V. A., A. S. Punjabi, and M. Lagunoff. 2008. Activation of Akt through gp130 receptor signaling is required for Kaposi's sarcoma-associated herpesvirus-induced lymphatic reprogramming of endothelial cells. J. Virol. 82:8771-8779.
38. Nagy, S., R. Gyulai, L. Kemeny, P. Szenohradszky, and A. Dobozy. 2000. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 69:2230-2231. (Pubitemid 30395072)
39. Neyts, J., and E. De Clercq. 1997. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob. Agents Chemother. 41:2754-2756.
40. Nguyen, H. Q., et al. 2008. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22:937-945. (Pubitemid 351652244)
41. Paparizos, V. A., K. P. Kyriakis, V. Papastamopoulos, M. Hadjivassiliou, and N. G. Stavrianeas. 2002. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J. Acquir. Immune Defic. Syndr. 30:257-258.
42. Parkin, D. M., S. L. Whelan, J. Ferlay, L. Teppo, and D. B. Thomas (ed.). 2002. Cancer incidence in five continents, vol. VIII. IARC scientific publication no. 155. International Agency for Research on Cancer, Lyon, France.
43. Parkin, D. M., H. Wabinga, S. Nambooze, and F. Wabwire-Mangen. 1999. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 13:2563-2570. (Pubitemid 30038035)
44. Pore, N., A. K. Gupta, G. J. Cerniglia, and A. Maity. 2006. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 8:889-895.
45. Rey, D., et al. 2001. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J. Acquir. Immune Defic. Syndr. 27:459-462.
46. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
47. Sgadari, C., et al. 2002. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. 8:225-232.
48. Sgadari, C., P. Monini, G. Barillari, and B. Ensoli. 2003. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol. 4:537-547. (Pubitemid 38351710)
49. Unal, A., et al. 1997. The protease and the assembly protein of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8). J. Virol. 71:7030-7038. (Pubitemid 27355369)
50. Venetsanakos, E., et al. 2002. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp. Cell Res. 273:21-33.
51. Vieira, J., P. O'Hearn, L. Kimball, B. Chandran, and L. Corey. 2001. Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J. Virol. 75:1378-1386. (Pubitemid 32094696)
52. Vieira, J., and P. M. O'Hearn. 2004. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 325:225-240.
53. Whitby, D., et al. 1995. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346:799-802.
54. Wijnveen, A. C., H. Persson, S. Bjorck, and I. Blohme. 1987. Disseminated Kaposi's sarcoma - full regression after withdrawal of immunosuppressive therapy: report of a case. Transplant. Proc. 19:3735-3736.
55. Yang, T. T., P. Sinai, P. A. Kitts, and S. R. Kain. 1997. Quantification of gene expression with a secreted alkaline phosphatase reporter system. Biotechniques 23:1110-1114.
56. Yang, Y., et al. 2006. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br. J. Cancer 95:1653-1662. (Pubitemid 44950790)
57. Yang, Y., et al. 2005. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci. 96:425-433. (Pubitemid 41179744)
58. Zhu, W., et al. 2005. Potent antiviral activity of north- methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus. Antimicrob. Agents Chemother. 49:4965-4973.